{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:07:36Z","timestamp":1791914856380,"version":"4.3.4"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.arbres.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:40:17Z","timestamp":1779550817000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Type 2 Endotypes in Airway Diseases"],"prefix":"10.1016","author":[{"given":"Angel","family":"Maldonado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"del Campo-Grijalba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Angelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2026.05.006_bib0595","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0600","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41573-023-00750-1","article-title":"Type 2 chronic inflammatory diseases: targets, therapies and unmet needs","volume":"22","author":"Kolkhir","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.arbres.2026.05.006_bib0605","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0610","doi-asserted-by":"crossref","first-page":"e20231236","DOI":"10.1084\/jem.20231236","article-title":"TL1A is an date epithelial alarmin that cooperates with IL-33 for initiation of allergic airway inflammation","volume":"221","author":"Schmitt","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0615","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01619-2023","article-title":"Airway remodelling in asthma and the epithelium: on the edge of a new era","volume":"63","author":"Varricchi","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib0620","series-title":"Global strategy for asthma management and prevention, 2025","year":"2025"},{"key":"10.1016\/j.arbres.2026.05.006_bib0625","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","year":"2026"},{"key":"10.1016\/j.arbres.2026.05.006_bib0630","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.arbres.2025.10.008","article-title":"Update 2025 of the Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD","volume":"61","author":"Miravitlles","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0635","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-physiol-042924-084007","article-title":"The developmental origins of asthma and COPD","volume":"88","author":"Polverino","year":"2026","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0640","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1042\/CS20160487","article-title":"Cellular and molecular mechanisms of asthma and COPD","volume":"131","author":"Barnes","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.arbres.2026.05.006_bib1185","series-title":"Asthma (ERS Monograph)","first-page":"1","article-title":"Innate and adaptive immune responses in asthma","author":"Palomares","year":"2025"},{"key":"10.1016\/j.arbres.2026.05.006_bib0650","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaci.2025.03.008","article-title":"Unraveling the heterogeneity of asthma: decoding subtypes of asthma","volume":"156","author":"Fuhlbrigge","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0655","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arbres.2024.09.007","article-title":"Airway remodeling in asthma: mechanisms, diagnosis, treatment, and future directions","volume":"61","author":"Tiotiu","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0660","article-title":"Inflammation mechanism and research progress of COPD","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0665","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2408466","article-title":"Eosinophilic inflammation: a key player in COPD pathogenesis and progression","volume":"56","author":"Lee","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0670","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2213-2600(18)30513-7","article-title":"Calling time on asthma deaths in tropical regions-how much longer must people wait for essential medicines?","volume":"7","author":"Asher","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0675","article-title":"Determining asthma endotypes and outcomes: complementing existing clinical practice with modern machine learning","volume":"3","author":"Ray","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0680","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2026.05.006_bib0685","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0690","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/cea.70084","article-title":"Mechanisms and treatment of type 2 high and low asthma endotypes","volume":"55","author":"Chin-See-Chong","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0695","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.arbres.2026.05.006_bib0700","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2026.05.006_bib0705","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jaip.2025.04.055","article-title":"Diagnosis and treatment options for T2-low asthma","volume":"13","author":"Thomas","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.arbres.2026.05.006_bib0710","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/JAA.S375325","article-title":"Characteristics of severe non-eosinophilic asthma: analysis of data from 1075 patients included in the FASE-CPHG study","volume":"16","author":"Portel","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0715","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/JAA.S153097","article-title":"Non-eosinophilic asthma: current perspectives","volume":"11","author":"Esteban-Gorgojo","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0720","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaci.2007.02.042","article-title":"Noneosinophilic asthma: a distinct clinical and pathologic phenotype","volume":"119","author":"Haldar","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0725","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0730","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2213-2600(21)00023-0","article-title":"Neutrophilic asthma: misconception or misnomer?","volume":"9","author":"Nair","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0735","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/all.15087","article-title":"An altered sputum macrophage transcriptome contributes to the neutrophilic asthma endotype","volume":"77","author":"Fricker","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0740","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/all.15487","article-title":"IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma","volume":"78","author":"Badi","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0745","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0750","doi-asserted-by":"crossref","first-page":"2301397","DOI":"10.1183\/13993003.01397-2023","article-title":"The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma","volume":"63","author":"Russell","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib0755","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/all.16318","article-title":"The epithelial barrier theory and its associated diseases","volume":"79","author":"Sun","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.05.038","article-title":"Defective epithelial barrier function in asthma","volume":"128","author":"Xiao","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0765","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1139\/Y08-004","article-title":"Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation","volume":"86","author":"de Boer","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008578","article-title":"Disordered microbial communities in asthmatic airways","volume":"5","author":"Hilty","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.arbres.2026.05.006_bib0775","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/all.70245","article-title":"Laundry detergents enhance sensitization to co-inhaled allergens and exacerbate airway inflammation in mice","volume":"81","author":"Nagano","year":"2026","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0780","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1038\/s41598-025-90261-3","article-title":"Effect of PM(2.5) exposure on susceptibility to allergic asthma in elderly rats treated with allergens","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.arbres.2026.05.006_bib0785","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nm.2731","article-title":"Innate and adaptive immune responses in asthma","volume":"18","author":"Holgate","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0790","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/all.15678","article-title":"Protease allergens as initiators-regulators of allergic inflammation","volume":"78","author":"Soh","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0795","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1265049","article-title":"Sensing of protease activity as a triggering mechanism of Th2 cell immunity and allergic disease","volume":"4","author":"Meloun","year":"2023","journal-title":"Front Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0800","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2025.02.018","article-title":"TL1A, a novel alarmin in airway, intestinal, and autoimmune disorders","volume":"155","author":"Varricchi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0805","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","article-title":"Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma","volume":"24","author":"Gauvreau","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.arbres.2026.05.006_bib0810","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/all.15609","article-title":"Sounding the alarmins \u2013 the role of alarmin cytokines in asthma","volume":"78","author":"Gauvreau","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0815","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/all.16337","article-title":"How type-2 dendritic cells induce Th2 differentiation: instruction, repression, or fostering T cell-T cell communication?","volume":"80","author":"Ronchese","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0820","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.arbres.2026.05.006_bib0825","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1038\/s41467-025-62632-x","article-title":"A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease","volume":"16","author":"Sevilla-Ortega","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.arbres.2026.05.006_bib0830","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaci.2025.05.002","article-title":"Cannabinoid WIN55,212-2 restores bronchial epithelium by regulating oxidative stress and STAT6 phosphorylation","volume":"156","author":"Perez-Diego","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0835","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/832560","article-title":"Nitric oxide in asthma physiopathology","volume":"2011","author":"Prado","year":"2011","journal-title":"ISRN Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0840","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.2147\/JIR.S531346","article-title":"IL-4 and IL-13 in cardiovascular disease: from immune modulation to therapeutic possibilities \u2013 a narrative review","volume":"18","author":"Kilic","year":"2025","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.arbres.2026.05.006_bib0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107872","article-title":"Single-cell and population transcriptomics reveal pan-epithelial remodeling in type 2-high asthma","volume":"32","author":"Jackson","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.arbres.2026.05.006_bib0850","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41556-021-00762-2","article-title":"Eosinophil extracellular traps drive asthma progression through neuro-immune signals","volume":"23","author":"Lu","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0855","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/s41591-025-03777-6","article-title":"Immune impacts of fire smoke exposure","volume":"31","author":"Johnson","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0860","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/ni.2131","article-title":"Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus","volume":"12","author":"Monticelli","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.06.009","article-title":"Neuropeptide CGRP limits group 2 innate lymphoid cell responses and constrains type 2 inflammation","volume":"51","author":"Nagashima","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.arbres.2026.05.006_bib0870","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/all.13760","article-title":"Inflammatory endotypes in COPD","volume":"74","author":"Barnes","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0875","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0880","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.2301","article-title":"Imbalance between subsets of CD8(+) peripheral blood T cells in patients with chronic obstructive pulmonary disease","volume":"4","author":"Chen","year":"2016","journal-title":"PeerJ"},{"key":"10.1016\/j.arbres.2026.05.006_bib0885","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.201408-1458OC","article-title":"Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease","volume":"191","author":"Christenson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0890","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.04.013","article-title":"Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles","volume":"141","author":"Ghebre","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0900","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib0905","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.arbres.2015.11.015","article-title":"Chronic obstructive pulmonary disease with eosinophilia, an emerging phenotype?","volume":"52","author":"Baloira Villar","year":"2016","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0910","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0915","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.3390\/jcm9082670","article-title":"Role of type 2 inflammatory biomarkers in chronic obstructive pulmonary disease","volume":"9","author":"Oishi","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0920","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arbres.2021.11.006","article-title":"T2 biomarkers as predictors of exacerbations of chronic obstructive pulmonary disease","volume":"58","author":"Alcazar-Navarrete","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0925","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/cyto.2002.1021","article-title":"Regulation of human eotaxin-3\/CCL26 expression: modulation by cytokines and glucocorticoids","volume":"17","author":"Banwell","year":"2002","journal-title":"Cytokine"},{"key":"10.1016\/j.arbres.2026.05.006_bib0930","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.163.3.1602","article-title":"A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils","volume":"163","author":"Shinkai","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0935","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/all.14661","article-title":"Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Higham","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib0940","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/thorax-2023-220972","article-title":"Type-2 inflammation and lung function decline in chronic airway disease in the general population","volume":"79","author":"Colak","year":"2024","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2026.05.006_bib0945","article-title":"Inhibition of IL-4Ralpha reduces CCL26 in bronchial epithelial cells from COPD patients","volume":"11","author":"Pesic","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.arbres.2026.05.006_bib0950","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.alit.2024.03.002","article-title":"Eosinophilic mucus diseases","volume":"73","author":"Arima","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.arbres.2026.05.006_bib0955","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-042220-015902","article-title":"The pathology of asthma: what is obstructing our view?","volume":"18","author":"Aegerter","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.arbres.2026.05.006_bib0960","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.chest.2023.11.033","article-title":"Silent airway mucus plugs in COPD and clinical implications","volume":"166","author":"Mettler","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2026.05.006_bib0965","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib0970","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2023.2065","article-title":"Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease","volume":"329","author":"Diaz","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.arbres.2026.05.006_bib0975","doi-asserted-by":"crossref","first-page":"1801291","DOI":"10.1183\/13993003.01291-2018","article-title":"Eosinophil-derived IL-13 promotes emphysema","volume":"53","author":"Doyle","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib0980","first-page":"8877","article-title":"IL-9 exacerbates the development of chronic obstructive pulmonary disease through oxidative stress","volume":"22","author":"Zou","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.arbres.2026.05.006_bib0985","doi-asserted-by":"crossref","first-page":"230229","DOI":"10.1183\/20734735.0229-2023","article-title":"Type 2 inflammation in COPD: is it just asthma?","volume":"20","author":"Beech","year":"2024","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.arbres.2026.05.006_bib0990","first-page":"127","article-title":"Reticular basement membrane in asthma and COPD: similar thickness, yet different composition","volume":"4","author":"Liesker","year":"2009","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2026.05.006_bib0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1000","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2500\/ajr.2006.20.2918","article-title":"The up-regulated expression of tenascin C in human nasal polyp tissues is related to eosinophil-derived transforming growth factor beta1","volume":"20","author":"Liu","year":"2006","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1164\/rccm.200203-183OC","article-title":"Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease","volume":"167","author":"Fabbri","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1190","series-title":"COPD in the 21st Century (ERS Monograph)","first-page":"149","article-title":"Eosinophils and COPD","author":"Beech","year":"2024"},{"key":"10.1016\/j.arbres.2026.05.006_bib1015","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04167-2020","article-title":"Stability of eosinophilic inflammation in COPD bronchial biopsies","volume":"56","author":"Higham","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib1020","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arbres.2026.05.006_bib1025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.202301-0149OC","article-title":"Eosinophil subtypes in adults with asthma and adults with chronic obstructive pulmonary disease","volume":"208","author":"Cabrera Lopez","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1030","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251335800","article-title":"Eosinophils in chronic obstructive pulmonary disease","volume":"19","author":"Vanetti","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.arbres.2026.05.006_bib1035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/all.14016","article-title":"Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma","volume":"75","author":"George","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib1040","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1417","article-title":"Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease","volume":"11","author":"Higham","year":"2022","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.arbres.2026.05.006_bib1045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/thorax-2022-219534","article-title":"Inhaled corticosteroid responses in COPD: do mast cells hold the answer?","volume":"78","author":"Higham","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2026.05.006_bib1050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1164\/rccm.201112-2142OC","article-title":"Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease","volume":"186","author":"Ballarin","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1164\/rccm.200906-0932OC","article-title":"Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease","volume":"181","author":"Andersson","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1060","doi-asserted-by":"crossref","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib1065","doi-asserted-by":"crossref","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib1070","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1075","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1080","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1085","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.arbres.2025.07.017","article-title":"Biological therapy in COPD management: current evidence, challenges and opportunities","volume":"61","author":"Singh","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1090","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1095","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2026.05.006_bib1100","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1105","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1110","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.006_bib1120","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4","volume":"66","author":"Singh","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.006_bib1125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/cea.14575","article-title":"Allergen immunotherapy for the prevention and treatment of asthma","volume":"55","author":"Batard","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib1130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jaip.2025.05.003","article-title":"Combination of allergen-specific immunotherapy with biologics in severe asthma: counterintuitive or rational?","volume":"13","author":"Larenas-Linnemann","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.arbres.2026.05.006_bib1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.02.029","article-title":"Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1","volume":"138","author":"Sirvent","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.06.012","article-title":"Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring","volume":"149","author":"Benito-Villalvilla","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1145","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1111\/all.15374","article-title":"First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy","volume":"77","author":"Nieto","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib1150","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/all.16387","article-title":"Short-course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy","volume":"80","author":"Mosges","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib1155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1431351","article-title":"Grass pollen allergoids conjugated with mannan for subcutaneous and sublingual immunotherapy: a dose-finding study","volume":"15","author":"Ojeda","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1160","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/cea.14261","article-title":"From trained immunity in allergy to trained immunity-based allergen vaccines","volume":"53","author":"Martin-Cruz","year":"2023","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib1165","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jaci.2024.09.009","article-title":"Trained immunity-based vaccines for infections and allergic diseases","volume":"154","author":"Martin-Cruz","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.arbres.2026.05.006_bib1170","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/all.16423","article-title":"Allergen-specific immunotherapy and trained immunity","volume":"80","author":"Martin-Cruz","year":"2025","journal-title":"Allergy"},{"key":"10.1016\/j.arbres.2026.05.006_bib1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110184","article-title":"Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections","volume":"38","author":"Brandi","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.arbres.2026.05.006_bib1180","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1164\/rccm.202003-0520OC","article-title":"Bacterial mucosal immunotherapy with MV130 prevents recurrent wheezing in children: a randomized, double-blind. Placebo-controlled Clinical Trial","volume":"204","author":"Nieto","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626001936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626001936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T19:20:37Z","timestamp":1780773637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289626001936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":118,"alternative-id":["S0300289626001936"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2026.05.006","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 2 Endotypes in Airway Diseases","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}